ArticleAmerican journal of cancer research2019
SORBS2, mediated by MEF2D, suppresses the metastasis of human hepatocellular carcinoma by inhibitiing the c-Abl-ERK signaling pathway.
Article in American journal of cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- SORBS2: A Molecular Nexus in Multisystem Diseases Through Scaffold-Mediated Regulation.Journal of cellular and molecular medicine · 2026Review
- Unveiling a new SORBS2::BRAF fusion in papillary thyroid carcinoma: insights from molecular diagnostics.Virchows Archiv : an international journal of pathology · 2026Article
- Construction and validation of a novel diagnostic model for esophageal squamous cell carcinoma: an integrated analysis of multi-omics data.Frontiers in immunology · 2026Article
- Inhibition of c-Abl suppresses the proliferation, invasion and migration of glioma cells.BMC cancer · 2025Article
- Evaluation of genetic instability of short tandem repeats in hepatocellular carcinoma.Scientific reports · 2025Article
- Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC.Frontiers in pharmacology · 2024Article
- Do or Die: HPV E5, E6 and E7 in Cell Death Evasion.Pathogens (Basel, Switzerland) · 2022Review
- Article
- Comprehensive Analysis of RAPGEF2 for Predicting Prognosis and Immunotherapy Response in Patients with Hepatocellular Carcinoma.Journal of oncology · 2022Article
- Novel oncogenes and tumor suppressor genes in hepatocellular carcinoma.Liver research (Beijing, China) · 2021Article
- Comprehensive characterization of pathological stage-related genes of papillary thyroid cancer along with survival prediction.Journal of cellular and molecular medicine · 2021Article
- Musk ketone induces apoptosis of gastric cancer cells via downregulation of sorbin and SH3 domain containing 2.Molecular medicine reports · 2021Article
- A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.Cancer medicine · 2021Article
- LncRNA H19 Inhibits the Progression of Sepsis-Induced Myocardial Injury via Regulation of the miR-93-5p/SORBS2 Axis.Inflammation · 2021Article
- RNA-binding protein SORBS2 suppresses clear cell renal cell carcinoma metastasis by enhancing MTUS1 mRNA stability.Cell death & disease · 2020Article
- Systematic Construction and Validation of an RNA-Binding Protein-Associated Model for Prognosis Prediction in Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
- A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The RBP sorbin and SH3 domain-containing 2 (SORBS2) has been reported to be a tumor suppressor and is dysregulated in several cancer types. Nonetheless, the exact function and mechanism of action of SORBS2 in hepatocellular carcinoma (HCC) remain unclear. In this study, we found that expression levels of SORBS2 were significantly lower in HCC tissues than that in normal tissue samples, and underexpression of SORBS2 was associated with lower overall survival tates of patients with HCC. In HCC cell lines, SORBS2 overexpression inhibited cell migration, invasion, and epithelial-mesenchymal transition, whereas SORBS2 inhibition yielded the opposite results.
Indexed as
Identifiers
31911856PMC6943356W3007326279What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.